Novartis defends Afinitor after thrashing from BMS and Exelixis trials
Novartis expects sales of Afinitor to slow after BMS and Exelixis announced this week their pipeline drugs beat it on renal cell carcinoma.
Archives for July 21, 2015
Court allows Sandoz to launch first US biosimilar in September
Novartis’ Sandoz unit will begin selling a biosimilar for Amgen’s cancer treatment Neupogen on September 2, thanks to an appeals court ruling released Tuesday.
Lonza: global hedge helped offset currency exposure but Visp still a risk
Lonza has reported higher revenues and profits for H1 2015, but warned that the strength of the Swiss franc means its Visp facility is still finding it hard to compete.
Flexibility replacing capacity in plant design, say engineering firms
Biomanufacturing needs are transitioning and as such there is no set model for facility design, say engineering firms TFS and NNE Pharmaplan.